Narcolepsy Market: Epidemiology, Therapies, Companies, DelveInsight | Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS P

Narcolepsy emerging therapies, such as AXS-12 (reboxetine), and others, are expected to boost the Narcolepsy Market in the upcoming years.

DelveInsight has launched a new report on "Narcolepsy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Narcolepsy market report @ https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Narcolepsy Market Report:

According to DelveInsight, the Narcolepsy market is projected to grow steadily between 2023 and 2032, driven by the introduction of new treatments and a rising incidence of the condition.
On October 16, 2024, the U.S. Food and Drug Administration (FDA) approved Lumryz (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients aged 7 years and older with narcolepsy. This once-nightly extended-release formulation offers a convenient dosing schedule, reducing the need for nighttime awakenings. Lumryz was first approved for adult use in May 2023. The pediatric approval includes Orphan Drug Exclusivity through October 2031. However, Lumryz carries a boxed warning due to its central nervous system depressant effects and potential for abuse and misuse. The drug is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).
On November 26, 2024, Axsome Therapeutics, Inc. reported that its investigational drug AXS-12 (reboxetine) met the primary endpoint in the ENCORE Phase 3 trial by significantly decreasing the frequency of cataplexy episodes compared to a placebo.
Key players in this market include Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS Pharmaceutics, Ono Pharma, Otsuka Pharmaceutical, Reset Therapeutics, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Vallon Pharmaceuticals, XWPharma, among others.
Promising Narcolepsy therapies include AXS-12 (reboxetine), and others.

Narcolepsy Overview

Narcolepsy is a long-term neurological condition that disrupts the brain's regulation of sleep and wakefulness. Individuals with this disorder often suffer from excessive daytime sleepiness (EDS), which can cause unexpected and uncontrollable bouts of sleep during daily activities. A key feature of narcolepsy is cataplexy-sudden muscle weakness triggered by intense emotions. Other associated symptoms can include sleep paralysis, vivid hallucinations, and fragmented sleep at night.

Narcolepsy Market Outlook

The narcolepsy therapeutics market report provides comprehensive insights into collaborations, acquisitions, mergers, licensing agreements, patents, and other key developments related to emerging therapies. The market is primarily driven by pharmacological treatments targeting symptoms such as cataplexy, excessive daytime sleepiness (EDS), and narcolepsy without cataplexy. Promising pipeline therapies-including BTD-001 (Balance Therapeutics), JZP-258 and Xyrem (Jazz Pharmaceuticals), TS-091 (Taisho Pharmaceutical), THN102 (Theranexus), and pitolisant (Bioprojet Pharma)-are expected to significantly reshape the narcolepsy treatment landscape in the near future.

Discover how the Narcolepsy market is rising in the coming years @ https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Narcolepsy Emerging Drugs
Dazukibart (PF-06823859): Pfizer

Scope of the Narcolepsy Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Narcolepsy Companies: Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS Pharmaceutics, Ono Pharma, Otsuka Pharmaceutical, Reset Therapeutics, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Vallon Pharmaceuticals, XWPharma, and others
Key Narcolepsy Therapies: AXS-12 (reboxetine), and others
Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies
Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Narcolepsy Unmet Needs, KOL's views, Analyst's views, Narcolepsy Market Access and Reimbursement

To know what's more in our Narcolepsy report, visit https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Narcolepsy Market Report:
Narcolepsy market report covers a descriptive overview and comprehensive insight of the Narcolepsy Epidemiology and Narcolepsy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Narcolepsy market report provides insights into the current and emerging therapies.
The Narcolepsy market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Narcolepsy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Narcolepsy market.

Got queries? Click here to know more about the Narcolepsy market Landscape https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Narcolepsy Patient Share (%) Overview at a Glance
5. Narcolepsy Market Overview at a Glance
6. Narcolepsy Disease Background and Overview
7. Narcolepsy Epidemiology and Patient Population
8. Country-Specific Patient Population of Narcolepsy
9. Narcolepsy Current Treatment and Medical Practices
10. Unmet Needs
11. Narcolepsy Emerging Therapies
12. Narcolepsy Market Outlook
13. Country-Wise Narcolepsy Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Narcolepsy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Narcolepsy Market Outlook 2034 https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Narcolepsy Pipeline Insights, DelveInsight

"Narcolepsy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Narcolepsy market. A detailed picture of the Narcolepsy pipeline landscape is provided, which includes the disease overview and Narcolepsy treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.